Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses SRPT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SRPT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Douglas Ingram | $1,171,425 | $0 | $6,000,005 | $0 | $649,000 | $0 | $20,236 | $7,840,666 |
| Chief Executive Officer | ||||||||
| Louise Rodino-Klapac | 752,505 | 0 | 2,603,966 | 822,879 | 260,000 | 0 | 16,920 | 4,456,270 |
| President, Research and Development and Technical Operations | ||||||||
| Ian Estepan | 740,529 | 0 | 2,603,966 | 822,879 | 260,000 | 0 | 17,019 | 4,444,392 |
| President, Chief Operating Officer | ||||||||
| Cristin Rothfuss | 629,858 | 0 | 2,603,966 | 822,879 | 159,450 | 0 | 17,470 | 4,233,623 |
| Executive Vice President, General Counsel | ||||||||
| Ryan Wong | 480,115 | 0 | 2,178,987 | 398,981 | 137,500 | 0 | 16,284 | 3,211,867 |
| Executive Vice President, Chief Financial Officer | ||||||||
| Dallan Murray | 373,095 | 0 | 825,034 | 822,879 | 0 | 0 | 721,782 | 2,742,790 |
| Former Executive Vice President, Chief Customer Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Douglas Ingram | $7,840,666 | $1,978,086 | $1,661,338 | +5,862,580 |
| Louise Rodino-Klapac | 4,456,270 | 2,737,283 | 3,718,991 | +1,718,987 |
| Ian Estepan | 4,444,392 | 2,752,522 | 3,705,626 | +1,691,870 |
| Cristin Rothfuss | 4,233,623 | — | — | — |
| Ryan Wong | 3,211,867 | — | — | — |
| Dallan Murray | 2,742,790 | 2,666,323 | — | +76,467 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kathryn J. Boor | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Stephen L. Mayo | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Deirdre Connelly | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Michael Chambers | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Richard J. Barry | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Hans Wigzell | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Claude Nicaise | Director | 2026-06-04 | A | 16,875 | — | — | RSU | Form 4 ↗ |
| Michael Severino | Director | 2026-07-28 | A | 756,104 | — | — | RSU | Form 4 ↗ |
| Michael Severino | Director | 2026-07-28 | A | 2,224,342 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ian Estepan | OPTION | 2025-03-10 | — | — | 16,644 | — | $822,879 |
| Douglas Ingram | PSU | 2025-12-07 | — | 123,001 | 123,001 | 246,002 | 0 |
| Cristin Rothfuss | RSU | 2025-03-10 | — | — | 8,276 | — | 825,034 |
| Dallan Murray | PSU | 2025-03-10 | — | 16,552 | 16,552 | 20,690 | 0 |
| Ian Estepan | PSU | 2025-09-03 | — | 50,000 | 50,000 | 50,000 | 0 |
| Louise Rodino-Klapac | PSU | 2025-09-03 | — | 50,000 | 50,000 | 50,000 | 0 |
| Dallan Murray | RSU | 2025-03-10 | — | — | 8,276 | — | 825,034 |
| Ryan Wong | OPTION | 2025-03-10 | — | — | 8,070 | — | 398,981 |
| Louise Rodino-Klapac | OPTION | 2025-03-10 | — | — | 16,644 | — | 822,879 |
| Cristin Rothfuss | OPTION | 2025-03-10 | — | — | 16,644 | — | 822,879 |
| Ryan Wong | PSU | 2025-09-03 | — | 25,000 | 25,000 | 25,000 | 0 |
| Ian Estepan | RSU | 2025-03-10 | — | — | 8,276 | — | 825,034 |
| Douglas Ingram | PSA | 2025-12-07 | — | 146,541 | 146,541 | 293,082 | 0 |
| Louise Rodino-Klapac | RSU | 2025-03-10 | — | — | 8,276 | — | 825,034 |
| Ryan Wong | RSU | 2025-09-03 | — | — | 93,875 | — | 1,778,931 |
| Douglas Ingram | RSU | 2025-12-07 | — | — | 269,542 | — | 6,000,005 |
| Cristin Rothfuss | RSU | 2025-09-03 | — | — | 93,875 | — | 1,778,931 |
| Cristin Rothfuss | PSU | 2025-03-10 | — | 16,552 | 16,552 | 20,690 | 0 |
| Ian Estepan | PSU | 2025-03-10 | — | 16,552 | 16,552 | 20,690 | 0 |
| Louise Rodino-Klapac | RSU | 2025-09-03 | — | — | 93,875 | — | 1,778,931 |
| Ryan Wong | RSU | 2025-03-10 | — | — | 4,013 | — | 400,056 |
| Dallan Murray | OPTION | 2025-03-10 | — | — | 16,644 | — | 822,879 |
| Ian Estepan | RSU | 2025-09-03 | — | — | 93,875 | — | 1,778,931 |
| Cristin Rothfuss | PSU | 2025-09-03 | — | 25,000 | 25,000 | 25,000 | 0 |
| Louise Rodino-Klapac | PSU | 2025-03-10 | — | 16,552 | 16,552 | 20,690 | 0 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ian Estepan | $2,603,965 | $0 | $822,879 | 0.0% |
| Douglas Ingram | 6,000,005 | 0 | 0 | 0.0% |
| Cristin Rothfuss | 2,603,965 | 0 | 822,879 | 0.0% |
| Dallan Murray | 825,034 | 0 | 822,879 | 0.0% |
| Louise Rodino-Klapac | 2,603,965 | 0 | 822,879 | 0.0% |
| Ryan Wong | 2,178,987 | 0 | 398,981 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ryan Wong | RSU | 93,875 | — | $2,020,190 |
| Louise Rodino-Klapac | RSU | 2,250 | — | 48,420 |
| Cristin Rothfuss | RSU | 25,000 | — | 538,000 |
| Ian Estepan | RSU | 93,875 | — | 2,020,190 |
| Cristin Rothfuss | PSU | 16,552 | — | 356,199 |
| Louise Rodino-Klapac | RSU | 4,500 | — | 96,840 |
| Ryan Wong | RSU | 4,013 | — | 86,360 |
| Ryan Wong | RSU | 25,000 | — | 538,000 |
| Ian Estepan | PSU | 1,250 | — | 26,900 |
| Louise Rodino-Klapac | RSU | 93,875 | — | 2,020,190 |
| Cristin Rothfuss | RSU | 1,050 | — | 22,596 |
| Ian Estepan | RSU | 2,000 | — | 43,040 |
| Ian Estepan | RSU | 8,276 | — | 178,100 |
| Ian Estepan | PSU | 16,552 | — | 356,199 |
| Ian Estepan | RSU | 8,125 | — | 174,850 |
| Ryan Wong | RSU | 625 | — | 13,450 |
| Ryan Wong | RSU | 312 | — | 6,714 |
| Cristin Rothfuss | RSU | 8,276 | — | 178,100 |
| Louise Rodino-Klapac | RSU | 2,000 | — | 43,040 |
| Cristin Rothfuss | RSU | 2,325 | — | 50,034 |
| Douglas Ingram | PSU | 146,541 | — | 3,153,562 |
| Louise Rodino-Klapac | RSU | 50,000 | — | 1,076,000 |
| Louise Rodino-Klapac | RSU | 8,276 | — | 178,100 |
| Cristin Rothfuss | RSU | 93,875 | — | 2,020,190 |
| Ian Estepan | RSU | 4,500 | — | 96,840 |
| Cristin Rothfuss | RSU | 1,500 | — | 32,280 |
| Ryan Wong | RSU | 900 | — | 19,368 |
| Louise Rodino-Klapac | PSU | 1,250 | — | 26,900 |
| Ian Estepan | RSU | 50,000 | — | 1,076,000 |
| Louise Rodino-Klapac | RSU | 8,125 | — | 174,850 |
| Douglas Ingram | PSU | 123,001 | — | 2,646,982 |
| Louise Rodino-Klapac | PSU | 16,552 | — | 356,199 |
| Ian Estepan | RSU | 2,250 | — | 48,420 |
| Ryan Wong | RSU | 1,350 | — | 29,052 |
The objectives of our executive officer compensation policies and programs are to attract and retain well-qualified senior executive management, to motivate their performance to attain clearly defined goals approved by the Board, and to align executives' long-term interests with those of our stockholders.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 45,185,398 | 22,373,065 | 134,544 | 66.88% | Passed |
| 2025 | 2025-06-05 | 72,144,292 | 2,176,998 | 62,710 | 97.07% | Passed |
| 2024 | 2024-06-06 | 63,631,197 | 9,004,619 | 206,561 | 87.6% | Passed |
| 2023 | 2023-06-08 | 20,368,530 | 52,772,697 | 648,115 | 27.85% | Failed |
| 2022 | 2022-06-02 | 62,746,933 | 4,465,735 | 59,518 | 93.36% | Passed |
| 2021 | 2021-06-03 | 60,029,842 | 1,448,156 | 119,026 | 97.64% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 66.88%a |
| 2025 | 2025-06-05 | 97.07%b |
| 2024 | 2024-06-06 | 87.6%c |
a. Approved under the standard stated in the filing — “As a result, abstentions and broker non-votes (if any) will have no effect on the proposal to approve the 2026 Plan.”.
b. Approved under the standard stated in the filing — “As a result, abstentions and broker non-votes (if any) will have no effect on the proposal to approve the amendment to the 2018 Plan.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 25 : 1 |
|---|---|
| CEO total compensation | $7,840,666 |
| Median employee compensation | $308,335 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| M. Kathleen BehrensIndependent · Board Chair · Audit (Chair) | $129,457 | $237,561 | $236,905 | $0 | $0 | $603,923 |
| Richard J. BarryIndependent · Audit · Nominating/Governance (Chair) | 102,813 | 237,561 | 236,905 | 0 | 0 | 577,279 |
| Hans WigzellIndependent · Nominating/Governance · Research and Development (Chair) | 88,000 | 237,561 | 236,905 | 0 | 0 | 562,466 |
| Deirdre ConnellyIndependent · Compensation (Chair) · Nominating/Governance | 83,687 | 237,561 | 236,905 | 0 | 0 | 558,153 |
| Stephen L. MayoIndependent · Audit · Research and Development | 82,500 | 237,561 | 236,905 | 0 | 0 | 556,966 |
| Claude NicaiseIndependent · Compensation · Research and Development | 80,000 | 237,561 | 236,905 | 0 | 0 | 554,466 |
| Kathryn J. BoorIndependent · Compensation · Nominating/Governance | 78,000 | 237,561 | 236,905 | 0 | 0 | 552,466 |
| Michael ChambersIndependent · Research and Development | 70,000 | 237,561 | 236,905 | 0 | 0 | 544,466 |
| Douglas S. IngramEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $475,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 16,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $714,457 |
| Equity awards (grant-date value) | $1,900,488 |
| All other compensation | $0 |
| Total cost of the board | $2,614,945 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Sarepta Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Sarepta Therapeutics, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corp. | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 4 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Vertex Pharmaceuticals | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 7 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 8 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 9 | Supernus Pharmaceuticals | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 10 | Alnylam Pharmaceuticals Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 12 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 13 | Ionis Pharmaceuticals Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 14 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 15 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 16 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 17 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 18 | Harmony Biosciences | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 19 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 20 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| — | argenx SE | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Alkermes plc | 130% | PSU 53 · RSU 24 · Options 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals Inc. | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| Amicus Therapeutics | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| argenx SE | not disclosed | not disclosed | not disclosed | not disclosed |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon (Human Capital Solutions practice, formerly Radford) |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences | 100% | not disclosed | not disclosed | Pay Governance |
| Incyte Corp. | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions practice) |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
| Vertex Pharmaceuticals | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Douglas Ingram | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 2 | Section 01, Louise Rodino-Klapac | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 4,456,270. Filing ↗machine: t34 · r14 · c25 · span 1556417–1556426 |
| 3 | Section 01, Ian Estepan | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 4,444,392. Filing ↗machine: t34 · r10 · c25 · span 1520942–1520951 |
| 4 | Section 01, Cristin Rothfuss | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 4,233,623. Filing ↗machine: t34 · r18 · c25 · span 1592056–1592065 |
| 5 | Section 01, Ryan Wong | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 3,211,867. Filing ↗machine: t34 · r6 · c25 · span 1489750–1489759 |
| 6 | Section 01, Dallan Murray | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Compensation Tables” · page 59. As printed: 2,742,790. Filing ↗machine: t34 · r23 · c24 · span 1633634–1633643 |
| 7 | Section 03, Ian Estepan OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r10 · c13 · span 1516723–1516730 |
| 8 | Section 03, Douglas Ingram PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r3 · c18 · span 1739583–1739590 |
| 9 | Section 03, Cristin Rothfuss RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r25 · c28 · span 1985003–1985010 |
| 10 | Section 03, Dallan Murray PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t8 · r10 · c0 · span 569076–569077 |
| 11 | Section 03, Ian Estepan PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r2 · c2 · span 1390783–1390789 |
| 12 | Section 03, Louise Rodino-Klapac PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r4 · c2 · span 1394426–1394432 |
| 13 | Section 03, Dallan Murray RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r23 · c9 · span 1628426–1628433 |
| 14 | Section 03, Ryan Wong OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r6 · c13 · span 1485623–1485630 |
| 15 | Section 03, Louise Rodino-Klapac OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “COMPENSATION COMMITTEE” · grants of plan-based awards table. Filing ↗machine: t34 · r14 · c13 · span 1552290–1552297 |
| 16 | Section 03, Cristin Rothfuss OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r18 · c13 · span 1587837–1587844 |
| 17 | Section 03, Ryan Wong PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t2 · r4 · c0 · span 233675–233676 |
| 18 | Section 03, Ian Estepan RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r13 · c28 · span 1854945–1854952 |
| 19 | Section 03, Douglas Ingram PSA | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r4 · c18 · span 1751253–1751260 |
| 20 | Section 03, Louise Rodino-Klapac RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 21 | Section 03, Ryan Wong RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r10 · c28 · span 1822596–1822605 |
| 22 | Section 03, Douglas Ingram RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r2 · c9 · span 1448810–1448819 |
| 23 | Section 03, Cristin Rothfuss RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r28 · c28 · span 2017666–2017675 |
| 24 | Section 03, Cristin Rothfuss PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t2 · r7 · c0 · span 238842–238843 |
| 25 | Section 03, Ian Estepan PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r12 · c16 · span 1839826–1839832 |
| 26 | Section 03, Louise Rodino-Klapac RSU | DEF 14A | — | 0001193125-26-177247 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 27 | Section 03, Ryan Wong RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r7 · c28 · span 1789893–1789900 |
| 28 | Section 03, Dallan Murray OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t34 · r23 · c13 · span 1629802–1629809 |
| 29 | Section 03, Ian Estepan RSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r2 · c3 · span 1391184–1391190 |
| 30 | Section 03, Cristin Rothfuss PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t2 · r7 · c0 · span 238842–238843 |
| 31 | Section 03, Louise Rodino-Klapac PSU | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t36 · r18 · c16 · span 1904811–1904817 |
| 32 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “CEO Pay Ratio”. As printed: 25 : 1. Filing ↗ |
| 33 | Section 08, M. Kathleen Behrens | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 603,923. Filing ↗ |
| 34 | Section 08, Richard J. Barry | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 577,279. Filing ↗machine: t15 · r4 · c17 · span 945074–945081 |
| 35 | Section 08, Hans Wigzell | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 562,466. Filing ↗ |
| 36 | Section 08, Deirdre Connelly | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 558,153. Filing ↗machine: t15 · r10 · c17 · span 985484–985491 |
| 37 | Section 08, Stephen L. Mayo | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 556,966. Filing ↗ |
| 38 | Section 08, Claude Nicaise | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 554,466. Filing ↗ |
| 39 | Section 08, Kathryn J. Boor | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 552,466. Filing ↗ |
| 40 | Section 08, Michael Chambers | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 544,466. Filing ↗machine: t15 · r8 · c17 · span 971869–971876 |
| 41 | Section 08, Douglas S. Ingram | DEF 14A | 2026-04-24 | 0001193125-26-177247 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 42 | Section 02, Kathryn J. Boor 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260263 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Stephen L. Mayo 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260261 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, M. Kathleen Behrens 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260257 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Deirdre Connelly 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Michael Chambers 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Richard J. Barry 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260245 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Hans Wigzell 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260259 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Claude Nicaise 2026-06-04 | Form 4 | 2026-06-05 | 0001193125-26-260250 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Michael Severino 2026-07-28 | Form 4 | 2026-07-29 | 0001193125-26-324445 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Michael Severino 2026-07-28 | Form 4 | 2026-07-29 | 0001193125-26-324445 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001193125-26-257501 | Item 5.07 · say-on-pay result. As reported: 66.88% (votes for as printed: 45,185,398). Filing ↗ |
| 53 | Section 06, 2025 vote | Form 8-K | 2025-06-06 | 0000950170-25-083131 | Item 5.07 · say-on-pay result. As reported: 97.07% (votes for as printed: 72,144,292). Filing ↗ |
| 54 | Section 06, 2024 vote | Form 8-K | 2024-06-07 | 0001193125-24-157458 | Item 5.07 · say-on-pay result. As reported: 87.6% (votes for as printed: 63,631,197). Filing ↗ |
| 55 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 56 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 57 | Section 09b board cost (computed) | Computed | — | computed | Cash 714,457 + equity 1,900,488 + all other 0 = 2,614,945, summed across the director compensation table rows.machine: formula: Σ = 2,614,945 |
| 58 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 59 | Incyte Corp., Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corp.'s own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 60 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 61 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 62 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 63 | Vertex Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 64 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 65 | United Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 66 | Supernus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 67 | Alnylam Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 68 | Blueprint Medicines, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: t150 · r5 · c14 · span 1101152–1101162 |
| 69 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 70 | Ionis Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 71 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 72 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 73 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 74 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 75 | Harmony Biosciences, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 76 | Sarepta Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 77 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 78 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 79 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 80 | Section 10a, Alnylam Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 81 | Section 10a, Supernus Pharmaceuticals reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 82 | Section 10a, Vertex Pharmaceuticals reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 83 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 84 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, United Therapeutics reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 87 | Section 10a, Harmony Biosciences reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 88 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 89 | Section 10a, Blueprint Medicines reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 90 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 91 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 92 | Section 10a, Ionis Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 93 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include Sarepta Therapeutics, Inc.. Filing ↗ |
| 94 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc. names Sarepta Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |